EPR26-165: Risk Factors for Infection in Chronic Lymphocytic Leukemia: Insights From a Real-World Cohort Treated With Bruton Tyrosine Kinase Inhibitors or Venetoclax.

Authors

• Divya Samat, Internal Medicine, Reading Hospital-Tower Health, West Reading, PAFollow
• Shivam Singh, Internal Medicine, Reading Hospital-Tower Health, West Reading, PAFollow

Document Type

Article

Publication Date

3-31-2026

Publication Title

J Natl Compr Canc Netw

Volume

24

Issue

3.5

Recommended Citation

Samat, D., & Singh, S. (2026). EPR26-165: Risk Factors for Infection in Chronic Lymphocytic Leukemia: Insights From a Real-World Cohort Treated With Bruton Tyrosine Kinase Inhibitors or Venetoclax.. J Natl Compr Canc Netw, 24 (3.5) https://doi.org/https://doi.org/10.6004/jnccn.2025.7185